SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread reports of users experiencing outages and technical issues, sparking frustration and concerns about the platform's reliability; some users are unable to access their accounts or execute trades. The issues are reportedly tied to a larger Amazon Web Services (AWS) outage, but the community is still expressing distrust and considering alternative platforms. Despite the technical difficulties, the stock price is up, leading to confusion and speculation about market manipulation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GME is trending as some traders draw comparisons to BYND's recent surge, speculating whether GME could see a similar short squeeze; the community is actively discussing prior squeezes and potential catalysts. Some investors express frustration with GME's performance, while others remain optimistic about its long-term potential amid growing discussions around meme stocks and short squeeze opportunities.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions about AI competition and its potential impact on Google's search dominance, with investors weighing the implications of new AI browser technologies. Community members are also focused on Google's AI investments and potential partnerships, particularly regarding its cloud infrastructure and Gemini AI model. Positive analyst ratings and potential earnings run-ups are contributing to the stock's current momentum.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to renewed community interest, possibly driven by its recent surpassing of a one-year high and BTIG adjusting their stance to a Buy rating with a target price of $40. Community members are actively discussing potential catalysts and upcoming opportunities related to the stock's momentum. The company's focus on novel therapies for immune-related diseases and recent financing updates may also contribute to the heightened attention.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong earnings and procedure growth, particularly with the da Vinci 5 system. The community is weighing the impact of tariffs and margin pressures against the company's long-term growth potential and market dominance in robotic surgery. Bullish sentiment is fueled by raised guidance and analysts' price targets, while some caution against high valuation and potential market volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's upcoming earnings and Elon Musk's compensation plan are driving much of the current discussion. Community members are actively debating potential earnings outcomes, forward guidance, and the impact of Musk's pay package on shareholder value and stock performance. Additionally, some traders point to technical indicators and unusual options activity as potential signals for the stock's direction.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a mixed Q3 earnings report and cautious forward guidance, sparking concerns about the near-term outlook despite a strong analog chip performance. Community discussions center on whether this drop represents a buying opportunity or signals deeper industry headwinds, with some analysts questioning the capital expenditure plan. Investors are also monitoring tariff implications and potential shifts in market share amid evolving US-China trade dynamics.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a recent $1 billion capital raise via a convertible note offering, sparking discussions about dilution and the company's financial strategy. While some investors express concerns about potential dilution, others view the raise as a bullish move to fund satellite constellation deployment and secure long-term growth. The community is actively analyzing the offering's terms and speculating on upcoming catalysts, including potential partnerships and launch milestones.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags ($FUN) is trending after NFL star Travis Kelce reportedly teamed up with activist investor Jana Partners to push for company changes. The community speculates about potential marketing strategies involving Kelce's fiance, Taylor Swift, while some express skepticism about the company's long-term prospects despite the recent investment news.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$NERV is trending due to a significant financing deal aimed at advancing its schizophrenia treatment through Phase 3 trials, sparking excitement among retail investors. Community discussions revolve around the potential FDA catalyst and the stock's potential for further gains. The stock's substantial pre-market surge and high trading volume reflect the market's reaction to the news and the renewed focus on the company's prospects in the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 280.1% in MBX Biosciences, Inc. (MBX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet

The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MBX Biosciences, Inc. (MBX) said on Monday that its once-weekly Canvuparatide achieved the primary endpoint with statistical significance at week 12 in its mid-stage trial in adult patients with chronic hypoparathyroidism.Hypoparathyroidism is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood. According to MBX, the disease affects more than 250,000 individuals in the U.S. and Europe.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved">noted</a> that 63% of Canvuparatide-treated patients in the study maintained serum calcium levels within the normal range and were independent of conventional therapy, including active vitamin D and calcium supplements, at week 12, with zero contribution from rescue therapy, compared to 31% in placebo-treated patients, the company stated.In the open-label extension of the trial, 79% of patients who received treatment achieved these milestones at six months. The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.Shares of the company soared 144% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MBX">MBX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Guggenheim subsequently raised its price target on MBX to $84 from $44 while keeping a ‘Buy’ rating on the shares. The results achieved the firm's "bull case," noted the analyst, who increased the firm's view of the odds of success for Canvuparatide to 75% from 50% previously. Guggenheim also argued that the data provides "clear line of sight to blockbuster-plus potential."CEO Kent Hawryluk said that the company is pleased with the results. “We believe the totality of the data support a once-weekly product profile with continuous infusion-like PTH exposure. These 12-week and 6-month results represent the potential for a meaningful improvement over current treatment options for HP patients and provide a strong foundation for further development,” he said.All doses of Canvuparatide were generally well-tolerated with no discontinuations related to the drug, and no treatment-related serious adverse events or discontinuations were recorded during the 12-week trial, the company said.MBX stock is down 46% this year and approximately 55% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.

Equity

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.


These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MBX
MBX Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MBX News

MBXMBX Biosciences Inc.